Medullary thyroid cancer (MTC) is a rare cancer which originates from specialized thyroid cells also called parafollicular cells, or C cells that are responsible for the secretion of calcitonin. This cancer represents about 3% of all thyroid cancers cases. There are two forms of MTC: sporadic form which is the most common form (70% of cases) and inherited form in nearly 30% of cases. MTC has biological specificity by the secretion of calcitonin, which can be used as a tumor biomarker for diagnosis and monitoring. Treatment involves surgery to remove the thyroid gland and surrounding lymph nodes, but treatment of MTC depends mainly on the stage of the cancer.
On the market since 2012, Vandatenib (CAPRELSA ®) is the first drug to be approved for treatment of late-stage (metastatic) medullary thyroid cancer in adult patients who are ineligible for surgery.The observational study CAPRELSA is being conducted to fulfil the specific obligation post-authorisation measure for the conditional marketing authorisation. It is carried on to confirm in real life conditions the benefit/risk of vandetanib 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC.
The hospital center of Luxembourg is involved and CIEC-LIH is actively assisting and supporting physicians involved in this trial. The total number of patients is 80 with approximately 2 patients in Luxembourg.
More information here: www.luxclin.lu/Studies/Details/?c=STP5104KTH
for articles/videos/studies
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.
